Xofluza 10 mg, Granulat zur Herstellung einer Suspension zum Einnehmen (Beutel)

7680680680025 CH-68068 J05AX25 08.03.0.

No images available

Details

Product number
6806802
CPT
-
Packaging group
2
Unit
Beutel
Composition
baloxavirum marboxilum 10 mg, mannitolum, maltitolum 175 mg, natrii chloridum corresp. natrium 5.9 mg, hypromellosum, povidonum K 25, silica colloidalis anhydrica, sucralosum, talcum, aromatica (Erdbeer) ad granulatum, pro charta.

Articles (1)

Xofluza 10 mg, Granulat zur Herstellung einer Suspension zum Einnehmen (Beutel)
Granulat
2
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
baloxavirum marboxilum
10.0 MG Substance Wirkstoff (Principe actif)
mannitolum
- Substance HNIDK
maltitolum
175.0 MG Substance HBESI
natrii chloridum
- Substance HNIDK
natrium
5.9 MG Substance HBESI
hypromellosum
- Substance HNIDK
povidonum K 25
- Substance HNIDK
silica colloidalis anhydrica
- Substance HNIDK
sucralosum
- Substance HNIDK
talcum
- Substance HNIDK
aromatica
- Substance AROMA

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
68068
Drug name
Xofluza, Granulat zur Herstellung einer Suspension zum Einnehmen
Galenic form
GRAS
ATC Code
J05AX25
Authorization status
Z
Dispensation category
B
First authorization
19/11/2021
Authorization expiration date
31/12/9999
IT number
08.03.0.
Domain
Human medicine
Field of application
Behandlung von Influenza, Influenza-Postexpositionsprophylaxe

Packaging details

Description (FR)
XOFLUZA susp 10 mg 2 pce
Description (DE)
XOFLUZA Susp 10 mg 2 Stk
Market launch
05/08/2026
Market withdrawal
05/08/2026
Narcotic (BTM)
No

Other packaging sizes

XOFLUZA gran 2 mg/ml pour susp fl 20 ml
1 FLAS
View
XOFLUZA susp 30 mg 1 pce
1 BEU
View
XOFLUZA susp 40 mg 1 pce
1 BEU
View
Buy us a coffee Explore the data